These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. Gobburu JV; Tammara V; Lesko L; Jhee SS; Sramek JJ; Cutler NR; Yuan R J Clin Pharmacol; 2001 Oct; 41(10):1082-90. PubMed ID: 11583476 [TBL] [Abstract][Full Text] [Related]
4. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Sramek JJ; Anand R; Wardle TS; Irwin P; Hartman RD; Cutler NR Life Sci; 1996; 58(15):1201-7. PubMed ID: 8614273 [TBL] [Abstract][Full Text] [Related]
5. Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Tse FL; Laplanche R Pharm Res; 1998 Oct; 15(10):1614-20. PubMed ID: 9794506 [TBL] [Abstract][Full Text] [Related]
7. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Farlow M; Anand R; Messina J; Hartman R; Veach J Eur Neurol; 2000; 44(4):236-41. PubMed ID: 11096224 [TBL] [Abstract][Full Text] [Related]
8. Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. Habucky K; Tse FL Biopharm Drug Dispos; 1998 Jul; 19(5):285-90. PubMed ID: 9673779 [TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Polinsky RJ Clin Ther; 1998; 20(4):634-47. PubMed ID: 9737824 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Enz A; Boddeke H; Gray J; Spiegel R Ann N Y Acad Sci; 1991; 640():272-5. PubMed ID: 1776750 [No Abstract] [Full Text] [Related]
13. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Hossain M; Jhee SS; Shiovitz T; McDonald C; Sedek G; Pommier F; Cutler NR Clin Pharmacokinet; 2002; 41(3):225-34. PubMed ID: 11929322 [TBL] [Abstract][Full Text] [Related]
14. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Kosasa T; Kuriya Y; Matsui K; Yamanishi Y Eur J Pharmacol; 1999 Sep; 380(2-3):101-7. PubMed ID: 10513568 [TBL] [Abstract][Full Text] [Related]
15. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate. Unni L; Vicari S; Moriearty P; Schaefer F; Becker R Methods Find Exp Clin Pharmacol; 2000; 22(1):57-61. PubMed ID: 10791297 [TBL] [Abstract][Full Text] [Related]
16. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Holsboer-Trachsler E; Hatzinger M; Stohler R; Hemmeter U; Gray J; Müller J; Kocher R; Spiegel R Neuropsychopharmacology; 1993 Jan; 8(1):87-92. PubMed ID: 8424849 [TBL] [Abstract][Full Text] [Related]
17. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow M; Potkin S; Koumaras B; Veach J; Mirski D Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489 [TBL] [Abstract][Full Text] [Related]
18. Rivastigmine. A review of its use in Alzheimer's disease. Spencer CM; Noble S Drugs Aging; 1998 Nov; 13(5):391-411. PubMed ID: 9829166 [TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Kosasa T; Kuriya Y; Matsui K; Yamanishi Y Eur J Pharmacol; 2000 Feb; 389(2-3):173-9. PubMed ID: 10688981 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Burns A; Spiegel R; Quarg P Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]